PROTAC vaccine: A new way to live attenuated vaccines

PROTAC vaccine: A new way to live attenuated vaccines

Bibliographic Details
Main Authors:	Zhen Li, Haiqing Bai, Xuetong Xi, Wen‐xia Tian, John Z.H. Zhang, Demin Zhou, Longlong Si
Format:	Article
Language:	English
Published:	Wiley 2022-10-01
Series:	Clinical and Translational Medicine
Subjects:	influenza live attenuated vaccine PROTAC targeted protein degradation
Online Access:	https://doi.org/10.1002/ctm2.1081

Similar Items

Recent Advances in Optically Controlled PROTAC
by: Muzi Ouyang, et al.
Published: (2023-11-01)

Recent Advances in PROTACs for Drug Targeted Protein Research
by: Tingting Yao, et al.
Published: (2022-09-01)

PROTACs targeting epigenetic proteins
by: Chao Zhang, et al.
Published: (2023-12-01)

Recent Advances in PROTAC-Based Antiviral Strategies
by: Haleema Ahmad, et al.
Published: (2023-01-01)

Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future
by: Rui Li, et al.
Published: (2022-12-01)

Recent advances of PROTACs technology in neurodegenerative diseases
by: Chao Wang, et al.
Published: (2023-09-01)

Estrogen Receptor-α Targeting: PROTACs, SNIPERs, Peptide-PROTACs, Antibody Conjugated PROTACs and SNIPERs
by: Arvind Negi, et al.
Published: (2022-11-01)

PROTACs: A novel strategy for cancer drug discovery and development
by: Xin Han, et al.
Published: (2023-06-01)

Proteolysis-targeting chimeras (PROTACs) in cancer therapy
by: Xinyi Li, et al.
Published: (2022-04-01)

Influenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza Vaccines
by: Saranya Sridhar, et al.
Published: (2015-04-01)

PROTACs in gastrointestinal cancers
by: Yu Chen, et al.
Published: (2022-12-01)

Application of PROTACs in target identification and validation
by: Yang Liu, et al.
Published: (2024-03-01)

Immune responses after live attenuated influenza vaccination
by: Kristin G.-I. Mohn, et al.
Published: (2018-03-01)

A New Master Donor Virus for the Development of Live-Attenuated Influenza B Virus Vaccines
by: Chantelle L. White, et al.
Published: (2021-06-01)

An instructive attempt on developing aptamer-constructed PROTAC for breast cancer treatment
by: Yuzhu Zhang, et al.
Published: (2022-12-01)

PROTAC-Based Protein Degradation as a Promising Strategy for Targeted Therapy in Sarcomas
by: Caterina Mancarella, et al.
Published: (2023-11-01)

Selective Degradation of Target Proteins by Chimeric Small-Molecular Drugs, PROTACs and SNIPERs
by: Minoru Ishikawa, et al.
Published: (2020-04-01)

From PROTAC to TPD: Advances and Opportunities in Targeted Protein Degradation
by: Siqi Wang, et al.
Published: (2024-01-01)

PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities
by: Xuelian Liu, et al.
Published: (2023-01-01)

Mutation L319Q in the PB1 Polymerase Subunit Improves Attenuation of a Candidate Live-Attenuated Influenza A Virus Vaccine
by: Aitor Nogales, et al.
Published: (2022-06-01)

Cost-Effectiveness of Intranasal Live-Attenuated Influenza Vaccine for Children: A Systematic Review
by: Kenneth Sik-Kwan Chan, et al.
Published: (2022-09-01)

Safety and Viral Shedding of Live Attenuated Influenza Vaccine (LAIV) in Chinese Healthy Juveniles and Adults: A Phase Ⅰ Randomized, Double-Blind, Placebo-Controlled Study
by: Li Li, et al.
Published: (2022-10-01)

Evaluating α-galactosylceramide as an adjuvant for live attenuated influenza vaccines in pigs
by: Bianca L. Artiaga, et al.
Published: (2022-08-01)

Discovery of oseltamivir-based novel PROTACs as degraders targeting neuraminidase to combat H1N1 influenza virus
by: Zhichao Xu, et al.
Published: (2022-06-01)

Influenza Virus Carrying a Codon-Reprogrammed Neuraminidase Gene as a Strategy for Live Attenuated Vaccine
by: Ji Dong, et al.
Published: (2023-02-01)

Safety, Immunogenicity, and Protective Efficacy of a Chimeric A/B Live Attenuated Influenza Vaccine in a Mouse Model
by: Ekaterina Stepanova, et al.
Published: (2021-01-01)

PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies
by: Nuwayo Ishimwe Sincere, et al.
Published: (2023-05-01)

Safety and Efficacy of Spray Intranasal Live Attenuated Influenza Vaccine: Systematic Review and Meta-Analysis
by: Giulia Perego, et al.
Published: (2021-09-01)

An overview of PROTACs: a promising drug discovery paradigm
by: Zi Liu, et al.
Published: (2022-12-01)

Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies
by: Xiaopeng Peng, et al.
Published: (2024-02-01)

MDM2-BCL-XL PROTACs enable degradation of BCL-XL and stabilization of p53
by: Mengyang Chang, et al.
Published: (2022-08-01)

Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy
by: Yujeong Moon, et al.
Published: (2023-01-01)

Immune Responses Elicited by Live Attenuated Influenza Vaccines as Correlates of Universal Protection against Influenza Viruses
by: Yo Han Jang, et al.
Published: (2021-04-01)

Synthesis and Biological Activity of a VHL-Based PROTAC Specific for p38α
by: Mónica Cubillos-Rojas, et al.
Published: (2023-01-01)

Increasing the Safety Profile of the Master Donor Live Attenuated Influenza Vaccine
by: Thomas A. Hilimire, et al.
Published: (2020-01-01)

Targeted Protein Degradation to Overcome Resistance in Cancer Therapies: PROTAC and N-Degron Pathway
by: Hanbyeol Kim, et al.
Published: (2022-08-01)

Tubulin Resists Degradation by Cereblon-Recruiting PROTACs
by: Ivana Gasic, et al.
Published: (2020-04-01)

Viral interference and the live-attenuated intranasal influenza vaccine: Results from a pediatric cohort with cystic fibrosis
by: Constantina Boikos, et al.
Published: (2017-06-01)

Generation and Characterization of Universal Live-Attenuated Influenza Vaccine Candidates Containing Multiple M2e Epitopes
by: Tatiana Kotomina, et al.
Published: (2020-11-01)

A Mechanistic Pharmacodynamic Modeling Framework for the Assessment and Optimization of Proteolysis Targeting Chimeras (PROTACs)
by: Robin Thomas Ulrich Haid, et al.
Published: (2023-01-01)